# Head and Neck Phase III Iressa Versus Methotrexate Refractory: Iressa Versus Methotrexate (IMEX)

> **NCT00206219** · PHASE3 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 477 (—)

## Conditions studied

- Squamous Cell Carcinoma of the Head and Neck

## Interventions

- **DRUG:** Gefitinib
- **DRUG:** methotrexate

## Key facts

- **NCT ID:** NCT00206219
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-11
- **Primary completion:** 2007-09
- **Final completion:** 2007-09
- **Target enrollment:** 477 (—)
- **Last updated:** 2011-01-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00206219

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00206219, "Head and Neck Phase III Iressa Versus Methotrexate Refractory: Iressa Versus Methotrexate (IMEX)". Retrieved via AI Analytics 2026-09-03 from https://api.ai-analytics.org/clinical/NCT00206219. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*